Loading
A phase 1/2 trial of YL201 and Atezolizumab in small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07407933 by MediLink Therapeutics (Suzhou) Co., Ltd., with 118 participants planned, started 2026-03-31 and due to reach its primary completion in 2028-11. Interventions recorded: YL201 and Atezolizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares YL201, Atezolizumab and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
Shares YL201 and the tag pipeline.
Shares Flatiron Health (Roche) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/